natgillin/translations-raw huggingface dataset:
Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. 
Odgovarajući farmaceutski nosači uključuju inertne krute diluente ili filere, sterilne vodene otopine i različita organska otapala.
The nucleic acid molecule according to claim 6, comprising a nucleotide sequence depicted in SEQ ID NO 89, or its conservative sequence variant. 
ID NO: 89, ili inačica njegovog nepromjenjivog slijeda, ili slijed nukleinskih kiselina opisan u SEQ ID NO: 90, ili inačica njegovog nepromjenjivog slijeda.
A compound selected from the group consisting of or a pharmaceutically acceptable salt of any of the foregoing. 
Spoj £1đa, Spojiiša, ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih.
The medium of claim 15, wherein the frame of the encoded digital audio signal complies with enhanced AC-3 bit stream syntax. 
Postupak prema zahtjevu 1, naznačen time da je okvir kodiranog digitalnog audio signala u skladu s poboljšanom AC-3 bitnom sintaksom toka.
The method of claim 1, wherein the biological sample is maternal blood, plasma, serum, urine or saliva. 
Postupak prema zahtjevu 1, naznačen time, da biološki uzorak je krv, plazma, serum, urin ili slina od trudnice.
The lipid compound according to claim 1, wherein the compound is present as its S enantiomer. 
7. - Lipidni spoj prema zahtjevu 5, pri čemu je spoj prisutan u obliku svojeg S enantiomera.
The coating material as recited in claim 1, wherein the filler is selected from the group consisting of a carbonate, a sulfate, a silicate, a silicic acid, and an oxide. 
Obložni materijal prema jednom od prethodnih zahtjeva, naznačen time, da su punila odabrana iz skupine koju čine karbonati, sulfati, silikati, silikoni 1 oksidi.
Final weight 624 g. 
Konačna težina 624
The formulation in the form of film, cutaneous stick, lip balm or lipstick according to claims 21 or 22 comprising, as active ingredients, plant extracts and optionally comprising dyes, fragrances and/or excipients. 
Formulacija u obliku filma, štapića za kožu, balzama za usne ili ruža u skladu s patentnim zahtjevima 21 ili 22, naznačena time, da kao aktivne sastojke sadržava biljne ekstrakte i po izboru sadržava boje, mirise 1 / ili ekscipijente.
In another embodiment, in formula (VI), R45 is selected from the group consisting of —H, —OH, methoxy and ethoxy. 
Spoj prema zahtjevu 29, pri čemu je Rus izabran iz skupine koju čine -H, OH, metoksi i etoksi.
The door according to claim 1, wherein a prestressing device (62) is configured to push the leading slat (40) relative to the pivoting lever (50) such that the sealing strip is moved into the open position. 
Vrata u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što imaju uređaj za prednaprezanje (62) koji tjera vodeću lamelu (40) u zadanom smjeru u odnosu na zakretnu polugu (50), osobito u položaj u mirovanju sustava za brtvljenje (60).
Preferably said hybridoma produces an antibody that inhibits the binding of a HLA-c allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of a HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors. 
Hibridom prema zahtjevu 12, gdje taj hibridom proizvodi protutijelo koje inhibira vezanje HLA-c alel molekule, koja ima Lys ostatak na položaju 80, za humani KIR2DLI receptor, i vezanje HLA-C alel molekule, koja ima Asn ostatak na položaju 80, za humane KIR2DL2/3 receptore.
an antisense oligomer which consists of a nucleotide sequence having deletion, substitution, insertion and/or addition of 1 to 5 nucleotides in the nucleotide sequence of SEQ ID NO: 1 or 2, and has an activity to cause skipping of the 51st exon in the human dystrophin gene; and the antisense oligomer which has a nucleotide sequence having at least 80% identity with a nucleotide sequence of SEQ ID NO: 1 or 2 and has an activity to cause skipping of the 51st exon in the human dystrophin gene. 
(b) antisensni oligomer koji se sastoji od nukleotidne sekvence koja ima deleciju, supstituciju, inserciju i/ili adiciju od 1 do 5 nukleotida u nukleotidnoj sekvenci SEQ ID NO: 1 ili 2, ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu; i (c) antisensni oligomer koji ima nukleotidnu sekvencu koja ima najmanje 80% istovjetnosti s nukleotidnom sekvencom SEQ ID NO: 1 ili 2 1 ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu.
The ophthalmic solution according to claim 1, wherein the N—(N-acetylcysteinyl-)chitosan or pharmaceutically acceptable salt thereof used for the preparation of the solution exhibits at a concentration of 0.5% in water at 25° C. a kinematic viscosity within the range of 1 to 15 mm2/s. 
Oftalmološka otopina prema bilo kojem od prethodnih zahtjeva, naznačena time da N-(N-acetilcisteinil-)kitozan korišten za pripremu otopine ima pri koncentraciji od 0,5% u vodi na 25 *C kinematski viskozitet unutar raspona od 1 do 15 mm'/s, poželjno 2 do 10 mm//s.
A composition according to claim 1, wherein the composition has been stored at an effective temperature so that the level of degradant is approximately equal to or less than about 1.5%, preferably approximately equal to or less than about 1.0% and more preferably approximately equal to or less than about 0.5%, on a weight-by-weight basis, and the degradant is H168/79. 
[image] gdje je količina proizvoda razgradnje približno jednaka ili manja od oko 1.5% iskazano na bazi mase i gdje je farmaceutski sastav pripremljen kao emulzija tipa ulja u vodi koja ima pH od oko 6 do oko 8.8.
This alternative example requires simpler mechanics for the magazine movement system, but more complicated mechanics for the doors. 
Ovaj alternativni primjer zahtjeva jednostavniju mehaniku sustava za pomicanje spremnika, ali zahtjeva kompliciraniju mehaniku za vrata,
At day 12, the culture was diluted to 1200 mL (dilution ratio of 1/3) by adding fresh and preheated medium SM-005 and then split into 3 roller bottles RB850 cm2, each containing 400 mL. 
12. dana stanična je kultura razrijeđena na 1200 mL (omjer razrjeđenja 1/3) dodatkom svježeg prethodno zagrijanog SM-005 medija i raspodijeljena u 3 roler-boce RB 850 cm", pri čemu je svaka sadržavala 400 mL.
In one aspect of the invention, the second non-treatment period will continue for about 20 to 36 days, more preferably from about 26 to about 30 days, and most preferably for about 28 days. 
Suhi sastav praškastog aerosola za uporabu prema zahtjevu 2 ili zahtjevu 6, naznačen time, da je prvi period liječenja u trajanju od 26 do 30 dana, poželjno traje 28 dana.
Portable machine according to claim 1 or 2, characterised in that said side guides (3) of the sheet of plastic material are connected integrally to said positioning means (30, 50) of the roll. 
Prijenosni stroj prema zahtjevu 1 ili 2, naznačen time da su spomenute vodilice (3) folije od plastičnog materijala spojeni u jednu cjelinu sa spomenutim uređajima za namještanje (30, 50) za namještanje role.
A product comprising recombinant human follicle stimulating hormone (FSH) for use in the treatment of infertility according to any preceding claim, wherein the product further comprises a salt comprising a pharmaceutically acceptable alkali metal cation selected from the group consisting of Na+- or K+- salts, or a combination thereof. 
Proizvod, koji sadrži rekombinantni folikulostimulirajući hormon (FSH) dobiven iz ljudske stanične linije za uporabu kod liječenja neplodnosti prema bilo kojem prethodnom zahtjevu, naznačen time da proizvod nadalje sadrži sol, koja sadrži farmaceutski prihvatljiv kation alkalijskog metala, koji je izabran iz skupine, koja sadrži Na*-ili K*- soli ili njihovu kombinaciju.
This invention relates to certan dihydropyridines, specifically to certain 1,4-dihydropyridines having a basic amino-containing group attached to the 2-position, which have utility as anti-ischaemic and antihypertensive agents. 
Izum se odnosi na postupak za dobivanje izvjesnih dihidropiridina, točnije na postupak ta dobi janje izvjesnih 1,4-dihidropiridina koji imaju baznu grupu koja sadrži amino grupu u 2-položaju i koji su korisni kao anti-iskemična 1 antihipertenzijska sredstva.
Furthermore, with the known devices there is no facility for the user to set a regulating pressure. 
Nadalje, uz postojeće uređaje, ne postoji način kako bi korisnik postavio regulirani pritisak.
The filler material is treated with a combination of a resin-compatibilizing surface agent and an agent, capable of enhancing strength in the inventive material by copolymerization of the surface treating groups. 
Materijalu za punjenje je dodana kombinacija površinskog sredstva koje je kompatibilno sa smolom i sredstvom, a koje može povećati snagu inventivnog materijala kopolimerizacijom površine tretiranih skupina.
A transgenic host according to claim 20, wherein the light chain encoding nucleic acid molecule is a germline sequence. 
Transgeni murinski sisavac prema zahtjevu 13, naznačen time, da je sekvenca zametka, ona sekvenca slabog lanca, koju kodira molekula nukleinske kiseline.
where: L, D denote an appropriate amino-acid chirality; 
LL, D označavaju odgovarajuću kiralnost aminokiseline, 10
The use of a compound of the formula I, and/or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of a disease or condition in the treatment of which alpha-7 receptor activation plays a role or is involved and/or in which alpha-7 receptor activity is involved, especially one or more of the disorders mentioned above. 
Spoj formule I prema bilo kojem zahtjevu 1 do 10, koji je u slobodnom bazičnom obliku ili u obliku farmaceutski prihvatljive dodatne kiselinske soli, naznačen time, da se upotrebljava za liječenje ili prevenciju bolesti ili stanja u kojima igra ulogu aktiviranje a7-nACRR ili je implicirano aktiviranje a7-nAChR.
Measuring changes in the detectable signal produced by each probe of (ii); and optionally including the following step after step (iii): 
(ili) mjerenja promjena u detektabilnom signalu dobivenom iz svake sonde u koraku (ii); uz mogući sljedeći korak nakon koraka (iii):
The present invention provides a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is selected from the group consisting of: rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disorder, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. 
Spoj za upotrebu prema zahtjevu 17, pri čemu je bolest izabrana iz grupe koja obuhvaća: upalne bolesti crijeva, reumatoidni artritis, psorijazu, kronični opstruktivni poremećaj pluća, psorijazni artritis, ankilozirajući spondilitis, neutrofilnu astmu, astmu koja je otporna na steroide, multiplu sklerozu, i sistemski lupus eritematozus.
by reacting a compound of formula (3), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group; 
reakcijom spoja sa formulom (3), ili njegove soli, [image] gdje je R1 vodikova ili dušikova zaštitna grupa;
The compound of claim 1, wherein the compound is prepared from a compound selected from the group consisting of 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole; 5-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole; 1,3-dihydro-1-hydroxy-2,1-benzoxaborole; and combinations thereof. 
Spoj prema patentnom zahtjevu 1, naznačen time što je spoj pripremljen od spoja odabranog iz grupe koja se sastoji od 5-fluoro-1,3-dihidro-1-hidroksi-2,1-benzoksaborola; 5-kloro-1,3-dihidro-1-hidroksi-2,1-benzoksaborola; 1,3-dihidro-1-hidroksi-2,1-benzoksaborola; i njihovih kombinacija.
The capsule according to claim 10 in soft or hard gelatin. 
Kapsula u skladu s patentnim zahtjevom 10, naznačena time što je u mekoj ili tvrdoj želatini.
The process of any one of claims 1 to 5, wherein the oxycodone hydrochloride composition has less than 15 ppm, less than 10 ppm, or less than 5 ppm of 14-hydroxycodeinone. 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 15 ppm.
A process for the preparation of a compound of the Formula I wherein, X1 is selected from O, NR1 or S; and X2 is selected from CH or N; wherein R1 is a nitrogen-protecting group, which comprises: the sequential reaction of a compound of the Formula II 
je odabran od O, NR1 ili S; a je odabran od CH ili N; pri čemu R1 je dušikova zaštitna skupina, naznačen time, da sadrži: sekvencijalnu reakciju spoja Formule II [image] sa,
The compound for use of claim 7, wherein said characterization of the non-Hodgkin's lymphoma phenotype of the patient as an activated B-cell subtype comprises measuring one or more of the following: 
Tvar za uporabu u skladu s patentnim zahtjevom 7, pri čemu navedena karakterizacija fenotipa non-Hodgkinovog limfoma kao aktiviranog B-staničnog podtipa obuhvaća mjerenje jednog ili više od sljedećeg:
The residue was purified once more using column chromatography (silica, gradient, hexane to ether). 
Ostatak se još jednom pročisti kromatografijom na koloni (silicij, gradijent, heksan do etera).
The pavement system of claim 1, wherein the second granular material of the capping layer comprises sand, gravel, or crushed stone. 
Sustav kolnika prema zahtjevu 1, naznačen time što drugi granulirani materijal pokrovnog sloja (90) sadrži pijesak, šljunak ili drobljeni kamen.
Inhibition of MMPs provides a means for treating disease states wherein inappropriate metalloprotease activity results in degradation of connective tissue and inflammation. DETAILED DESCRIPTION OF THE INVENTION 
Inhibiranje MMP osigurava način liječenja bolesnih stanja u kojima neodgovarajuća aktivnost metaloproteaza uzrokuje razgradnju vezivnog tkiva i upalu.
building a signal frame based on the preamble data symbols and the data slice, the preamble data symbols comprising Layer 1,L1, signaling information for signaling the data slice; modulating the built signal frame by an Orthogonal Frequency Division Multiplexing, OFDM, method; and 
izgradnja okvira signala na temelju simbola podataka početnog niza i PLP simbola podataka s umetnutim vremenom unutar podatkovnog reza, simboli podataka početnog niza obuhvaćaju informaciju signaliziranja razine 1, L1, za signaliziranje podatkovnog reza;
According to the disclosure, in compounds of formula I: 
Formulacija izoliranog spoja formule I: gdje:
In certain embodiments of the invention, the sphingosine-1-phosphate receptor modulator is administered to the subject both prior to and after the onset of symptoms of the autoimmune disorder. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da se sastav daje subjektu prije ili poslije nastanka simptoma kronične upalne demijelinacijske polineuropatije.
The method for molding interior and exterior members of vehicles according to claim 1, wherein the step of molding the interior and exterior members is the step of molding the interior and exterior members by injection molding of resin. 
Postupak oblikovanja unutarnjih i vanjskih dijelova (4) vozila u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je korak oblikovanja unutarnjih i vanjskih dijelova (4) korak oblikovanja unutarnjih i vanjskih dijelova (4) oblikovanjem smole injektiranjem.
removing the G groups to form a compound of formula (XVIII): 
(đ) uklanjanje G grupa da bi se formiralo spoj formule (XVIII):
The antagonist or use of claim 6, wherein the parental administration is selected from the group consisting of: subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion. 
Postupak prema patentnom zahtjevu 14 ili antagonist za uporabu prema patentnom zahtjevu 14, pri čemu je navedeni heterologni polipeptid izabran iz grupe koju čine imunoglobulinska zglobna regija i Fc, humani serum albumin i histidinski obilježivač.
R, for each occurrence, is independently selected from the group consisting of -H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit -(CH2CH2O)n-Rc, an optionally substituted aryl having 6 to 18 carbon atoms, an optionally substituted 5-to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 3- to 18-membered heterocyclic ring containing 1 to 6 heteroatoms independently selected from O, S, N and P; 
R je za svako pojavljivanje neovisno odabran od skupine koja sadrži -H, izborno supstituirani linearni, razgranati ili ciklični alkil, alkenil ili alkinil koji ima 1 do 10 ugljikovih atoma, polietilensku glikolnu jedinicu -(CH2CH2O)n-Rc, izborno supstituirani aril koji ima 6 do 18 ugljikovih atoma, izborno supstituirani 5-člani do 18-člani heteroarilni prsten koji ima jedan ili više heteroatoma neovisno odabranih od dušika, kisika i sumpora ili izborno supstituirani 3-člani do 18-člani heterociklični prsten koji ima 1 do 6 heteroatoma neovisno odabranih od O, S, N i P;
A conjugated nucleic acid molecule which has the following formula: wherein N is a nucleotide, n is an integer from 15 to 195, the underlined N refers to a nucleotide having a modified phosphodiester backbone, the linker L' is selected from the group consisting of hexaethyleneglycol, tetradeoxythymidylate (T4), 1,19-bis(phospho)-8-hydraza-2-hydroxy-4-oxa-9-oxo-nonadecane and 2,19-bis(phosphor)-8-hydraza-1-hydroxy-4-oxa-9-oxo-nonadecane; m is 1 and L is a carboxamido oligoethylene glycol, C is selected from the group consisting of single or double chain fatty acids, tocopherol, folates or folic acid, cholesterol, a sugar or oligosaccharide, a peptide, and protein. 
. Konjugirana molekula nukleinske kiseline, naznačena time što ima jednu od sljedećih formula:, gdje se podcrtani nukleotid odnosi na nukleotid koji ima ili koji nema fosforotioatnu ili metilfosfonatnu okosnicu, vezani L’ se bira iz skupine koju čine heksaetilen-glikol, tetradeoksitimidilat (T4) i 2,19-bis(fosfor)-8-hidraza-1-hidroksi-4-oksa-9-oksononadekan; m je 1, L je karboksamidooligoetilen-glikol, a C se bira iz skupine koju čine dioleoil, oktadecil, folna kiselina, tokoferol i kolesterol.
An oral formulation in tablet form according to claim 1, wherein the tablet further comprises 10% to 50% weight percent microcrystalline cellulose. 
Oralna formulacija u obliku tablete u skladu s patentnim zahtjevom 1, naznačena time što tableta dodatno sadrži 10% do 50%, težinski, mikrokristalne celuloze.
In a further embodiment of the invention, the pre-cut part may have a holder adjacent to the wall section to open the wall section more easily. 
Spremnik (1) prema jednom od prethodnih patentnih zahtjeva, naznačen time da prethodno odrezani dio (6) ima držač za lagano otvaranje dijela stijenke (4) koje graniči s dijelom stijenke (4).
The naltrexone or a pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof for use, the use of the same, or the kit according to any of claims 1-14, wherein said naltrexone or pharmaceutically acceptable salt thereof and said bupropion or pharmaceutically acceptable salt thereof are administered for at least 28 weeks or for at least 56 weeks. 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da se navedeni naltrekson ili njegova farmaceutski prihvatljiva sol i navedeni bupropion ili njegova farmaceutski prihvatljiva sol daju tijekom najmanje 28 tjedana.
Therefore, the length of the spines or spikes 22 has to be from 5% to 200%, preferably from 40% to 150%, especially preferred from 50%-110% of the insulation layer thickness. 
- < spojni elementi (22) prodiru u izolacijski materijal (50), dužina spojnih elemenata (22) jest 40% do 150% debljine izolacijskog materijala, i
The compound, pharmaceutically acceptable salt thereof or pharmaceutical composition for use as claimed in claim 9, wherein said method comprises administering said compound, pharmaceutically acceptable salt thereof or pharmaceutical composition by injection to the human having or at risk of having the infection. 
Spoj, njegova farmaceutski prihvatljiva sol ili farmaceutski sastav za upotrebu prema zahtjevu 9, pri čemu spomenuti postupak obuhvaća primjenu spomenutog spoja, njegove farmaceutski prihvatljive soli ili farmaceutskog sastava ubrizgavanjem čovjeku koji ima ili je u riziku da dobije infekciju.
The smoking article of the present invention is described in greater detail in the accompanying drawings and in the detailed description of the invention which follow. 
Cigaretni substitut iz sadašnjeg izuma opisan je detaljnije na pratećim crtežima 1 u detaljnijem opisu izuma koji slijedi.
Combination of the compounds in the present invention with conventional antipsychotic drugs could also provide an enhanced therapeutic effect for the treatment of schizophrenic disorders, as described above for manic disorders. 
Kombinacija spojeva u prikazanom izumu sa konvencionalnim antipsihotičkim lijekovima bi također mogla osigurati pojačan terapeutski učinak za liječenje poremećaja shizofrenije, kao što je gore opisano za manične poremećaje.
Process according to any of Claims 1 to 6, wherein the water-soluble silicate compound is selected from sodium silicate, potassium silicate, waterglass, aluminium silicate, tricalcium silicate, dicalcium silicate, calcium silicate, silicic acid, sodium metasilicate and/or potassium metasilicate. 
Uporaba prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time da silikatni spoj topiv u vodi je izabran od natrij silikata, kalij silikata, natrij silikata, aluminij silikata, kalcij silikata, dikalcij silikata, dikalcij silikata, silicijeve kiseline, natrij metasilikata i/ili kalij metasilikata.
A composition for use according to claim 1 wherein the adherent-invasive Escherichia coli strain is LF82, 07081, 07082, 07076 or 06075. 
Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu je prijanjajuće-invazivni soj Escherichije coli I.F82, 07081, 07082, 07076 ili 06075.
Superframe length (16 bits) number of frames per superframe 
(97) Broj objave europskog patenta:
The product was filtered and dried in vacuum (30-50 mbar) at a temperature of 30-35°C. The drying was controlled by measuring the water content as described in Example 8 and the loss on drying. 
Dobiveni produkt je bio filtriran i osušen u vakuumu (30-50 mbara) na temperaturi od 30-35 *C. Sušenje je bilo kontrolirano mjerenjem količine vode kako je opisano u Primjeru 8 i gubitka tijekom sušenja.
with different doses of the compounds of the invention or vehicle only (placebo intact, placebo orx) with a volume of 1 ml/kg (n=5). 
davane različite doze spojeva prema ovom izumu ili samo vehikuluma (placebo za normalne, placebo za orx), u volumenu od 1 ml/kg (n = 5).
The multi-armed polymer prodrug of embodiment 33, wherein the overall nominal average molecular weight of the prodrug ranges from about 20,000 to about 80,000. 
Višestruko razgranati polimerni prolijek iz patentnog zahtjeva 1, pri čemu je ukupna prosječna molekulska masa prolijeka u rasponu od 20 000 do $0 000 Daltona.
Polydextrose is present in an amount of 30 to 60 weight %, preferably 40 to 55 weight %. 
Polidekstroza je prisutna u količini od 30 do 60 težinskih %, pri čemu se prednost daje količini od 40 do 55 težinskih %.
A dose counter according to 7 or 8, wherein the second ratchet drive pawl is resiliently biased into contact with the gear teeth of the gear wheel with which it is arranged for engagement, the pawl being displaceable away from the gear wheel against the bias. 
Brojač doza u skladu s patentnim zahtjevima 2 ili 3, pri čemu je drugi pogon zapornog zaklopca (132) elastično odmaknut u kontaktu sa zupcima zupčanika kotača sa zupčanikom s kojim je postavljen za pokretanje, zaklopac se može odmaknuti od kotača sa zupčanikom naspram odstupanju.
The antibody of claim 4, wherein at least about 20% to about 100% of the N-linked oligosaccharides in the Fc region are nonfucosylated. 
Protutijelo u skladu sa zahtjevom 7, naznačeno time, da su najmanje 20% do 100% N-vezanih oligosaharida u Fc regiji nefukozilirani.